Huandao Conditioning Application for Allergic Rhinitis Treatment

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBuddhist Tzu Chi General Hospital

About this trial

The goal of this clinical trial is to learn if the Huandao Conditioning Application works to treat allergic rhinitis in adults. It will also learn about the safety of this application. The main questions it aims to answer are:

Does the Huandao Conditioning Application improve allergic rhinitis symptoms as measured by the Rhinitis Control Assessment Test (RCAT) and nasal airway resistance tests? What medical problems do participants have when using the Huandao Conditioning Application?

Researchers will compare the therapeutic version of the application to a placebo version (a look-alike application that contains no therapeutic effect) to see if the Huandao Conditioning Application works to treat allergic rhinitis.

Participants will:

Use either the therapeutic or placebo version of the application daily for 1 week in Phase 1 Take a 2-week break with no application use Use the opposite version of the application daily for 1 week in Phase 2 Visit the clinic at the beginning and end of each phase for checkups and tests Complete symptom assessment questionnaires before each application use and 1-2 hours after use Be monitored for any adverse reactions throughout the study period

Eligibility criteria

Qualifiers

Age ≥ 18 years

RCAT score < 21

Positive allergen screening (> 0.35 KU/L for house dust, microbial, or pet dander)

Capable of operating mobile app and completing follow-up

Disqualifiers

Recent diagnosis, active treatment, or recurrence risk of head/neck cancer

Current or previous immunotherapy

Any condition that may compromise participant safety or interfere with trial assessment per investigator judgment

Trial design

Treatments tested in this trial

  • Huandao Conditioning Application
  • Placebo Huandao Conditioning App

Treatment groups

95 Participants
are divided into 2 treatment groups

Locations

This trial has no locations